First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS).

The matching criteria were gestation (using an ultrasound crown–rump length or biparietal diameter measurement), duration of storage, and centre. Screening performance of the individual markers and combinations of markers together with maternal age was assessed using standard methods. In addition pairs of first and second trimester serum samples from 600 controls were tested to secure a larger set in which screening performance could be deter­ mined using distribution parameters based on dates (time since first day of the last menstrual period).

[1]  S. Cicero,et al.  Absence of nasal bone in fetuses with trisomy 21 at 11–14 weeks of gestation: an observational study , 2001, The Lancet.

[2]  D. Krantz,et al.  Maternal serum Down syndrome screening: free beta-protein is a more effective marker than human chorionic gonadotropin. , 1990, American journal of obstetrics and gynecology.

[3]  H. Cuckle,et al.  Maternal serum screening for Down's syndrome: the effect of routine ultrasound scan determination of gestational age and adjustment for maternal weight , 1992, British journal of obstetrics and gynaecology.

[4]  Wilson Rd.  Amniocentesis and chorionic villus sampling. , 2000 .

[5]  S. Abbs,et al.  Development and implementation of a new rapid aneuploidy diagnostic service within the UK National Health Service and implications for the future of prenatal diagnosis , 2001, The Lancet.

[6]  A. Mcguire,et al.  Antenatal Screening for Down's Syndrome , 1997, Journal of medical screening.

[7]  E. Robertson,et al.  Improved performance in a prenatal screening programme for Down's syndrome incorporating serum‐free hCG subunit analyses , 1992, Prenatal diagnosis.

[8]  K. Nicolaides,et al.  Intrauterine lethality of trisomy 21 fetuses with increased nuchal translucency thickness , 1996, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[9]  K. Spencer,et al.  Free Beta Human Choriogonadotropin in Down's Syndrome Screening: A Multicentre Study of its Role Compared with other Biochemical Markers , 1992, Annals of clinical biochemistry.

[10]  A. Mackinson,et al.  First and Second Trimester Antenatal Screening for Down's Syndrome: The Results of the Serum, Urine and Ultrasound Screening Study (SURUSS) , 2003, Journal of medical screening.

[11]  K. Klinger,et al.  Fetal gender and aneuploidy detection using fetal cells in maternal blood: analysis of NIFTY I data , 2002, Prenatal diagnosis.

[12]  J. Moutquin,et al.  Screening for Down syndrome during the first and second trimesters: impact of risk estimation parameters. , 1995, Clinical biochemistry.

[13]  N. Wald,et al.  Tests using multiple markers , 2000 .

[14]  R. Salonen,et al.  A new simple and rapid dual assay for AFP and free β hCG in screening for Down syndrome , 1994, Clinical genetics.

[15]  J. Connor,et al.  Prenatal screening for chromosome abnormalities using maternal serum chorionic gonadotrophin, alpha‐fetoprotein, and age , 1991, Prenatal diagnosis.

[16]  K. Spencer.  Evaluation of an assay of the free beta-subunit of choriogonadotropin and its potential value in screening for Down's syndrome. , 1991, Clinical chemistry.

[17]  M. Sculpher,et al.  Screening for Down's syndrome: effects, safety, and cost effectiveness of first and second trimester strategies. , 2001, BMJ.

[18]  A. Lyon,et al.  Dimeric inhibin A as a marker for Down's syndrome in early pregnancy. , 1996, The New England journal of medicine.

[19]  T. Reynolds.  Absence of nasal bone and detection of trisomy 21 , 2002, The Lancet.

[20]  W. Holzgreve,et al.  Prenatal diagnosis using fetal cells and free fetal DNA in maternal blood. , 2001, Clinics in perinatology.

[21]  N. Wald,et al.  Fetal loss in Down syndrome pregnancies , 1999, Prenatal diagnosis.

[22]  P. Royston,et al.  Model-based screening by risk with application to Down's syndrome. , 1992, Statistics in medicine.

[23]  H. Cuckle,et al.  COMBINING INHIBIN A WITH EXISTING SECOND‐TRIMESTER MARKERS IN MATERNAL SERUM SCREENING FOR DOWN'S SYNDROME , 1996, Prenatal diagnosis.

[24]  J. Canick,et al.  Maternal serum screening for Down's syndrome in early pregnancy. , 1988, BMJ.

[25]  L. Levett,et al.  A large‐scale evaluation of amnio‐PCR for the rapid prenatal diagnosis of fetal trisomy , 2001, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[26]  K. Spencer,et al.  Dual Analyte Immunoassay—a New Approach to Neural Tube Defect and Down's Syndrome Screening , 1992, Annals of clinical biochemistry.